Experimental CAR-T therapy aims to tame stubborn Graves' disease

NCT ID NCT07333677

Recruiting now Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests HN2301, a new type of CAR-T therapy given directly into the blood, for people with refractory Graves' disease—a thyroid condition that doesn't respond well to standard treatments. The therapy reprograms the body's own immune cells to target and calm the overactive immune response. Five participants will receive several doses and be monitored for safety and signs of remission over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HN2301 (in vivo CAR-T therapy)
What this could lead to: If it works, this could offer a new treatment option for people with refractory Graves' disease, potentially achieving remission without long-term medication.
What could go wrong: This is a very early, small trial with only 5 participants. The therapy is experimental, and safety and effectiveness are not yet proven. There may be unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRAVES DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Graves disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAVES DISEASE

Contacts and locations

Locations

Zhongshan Hospital Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.